530-08-5 Usage
Description
Isoetharine, also known as Isoetarine, is a direct-acting sympathomimetic drug with relatively low selectivity for β2-adrenoreceptors. It was the first β2-selective drug widely used for the treatment of airway obstruction. Isoetharine is a β2-agonist and is resistant to MAO due to the presence of the β2-directing β-ethyl group and -directing isopropyl group. However, it is metabolized by COMT and O-sulfated quite effectively, resulting in a short duration of action similar to that of ISO. It is used only by inhalation for the treatment of acute episodes of bronchoconstriction.
Uses
Used in Respiratory Applications:
Isoetharine is used as a bronchodilator for treating acute episodes of bronchoconstriction. It quickly calms bronchospasms better than more selective bronchodilators, making it an effective treatment for patients experiencing respiratory distress.
Used in Chronic Obstructive Pulmonary Disease (COPD) Treatment:
Isoetharine is used as a bronchodilator for treating chronic obstructive illnesses of the outer respiratory tract. Its effectiveness in calming bronchospasms makes it a valuable asset in managing the symptoms of COPD.
Brand Name:
Isoetharine is available under the brand name Bronkometer, manufactured by Sanofi Aventis.
Originator
Dilabron,Sterling Winthrop
Manufacturing Process
36 g 3,4dibenzyl-hydroxy-butyrophenone was dissolved in 125 ml methylene
chloride and 16 g bromine was added dropwise after 15 g calcium carbonate.
An obtained precipitate was filtered off. The filtrate was distilled to dryness to
give 1-(3,4-dibenzyloxy-phenyl)-2-bromo-butan-1-one. It was dissolved in a
portion of ethanol and 15 g of isopropylamine was added. The mixture had
stood for night at room temperature and thereafter ether was added. The
isopropylamine hydrobromide had fallen. It was filtered off, the filtrate was
shook with 200 ml of diluted hydrochloric acid. At that 4-(1-hydroxy-2-
isopropylamino-butyl)-benzene-1,2-diol chlorohydrate was separated as an oil.
The oil was diluted with the 5 volumes of ethanol and the calculated quantity
hydrogen was passed through in a presence of palladium on coal catalyst. The
catalyst was filtered off and a solvent was removed to dryness, the residue
had crystallized by grinding with acetone. The obtained 4-(1-hydroxy-2-
isopropylamino-butyl)-benzene-1,2-diol chlorohydrate was recrystallized from
methanol. MP: 212°-213°C. Chlorohydrate may be changed into isoetharine
with the calculated quantity of any base.
Therapeutic Function
Sympathomimetic, Bronchodilator
Synthesis
Isoetharine, 3,4-dihydroxy-α-[1-(iso-propylamino)propyl]benzylic alcohol
(11.1.11), differs from isoproterenol in the presence of an additional ethyl group in the ethylamino side chain—and is synthesized by bromination of 3,4-dibenzyloxybutyrophenone and
the subsequent reaction of the resulting bromo derivative (11.1.9) with isopropylamine. The
product (11.1.10) undergoes reduction by hydrogen using a palladium catalyst, during which
the carbonyl group is simultaneously reduced and the benzyl-protecting group is removed,
forming isoetharine (11.1.11) [15].
Check Digit Verification of cas no
The CAS Registry Mumber 530-08-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,3 and 0 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 530-08:
(5*5)+(4*3)+(3*0)+(2*0)+(1*8)=45
45 % 10 = 5
So 530-08-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H21NO3/c1-4-10(14-8(2)3)13(17)9-5-6-11(15)12(16)7-9/h5-8,10,13-17H,4H2,1-3H3
530-08-5Relevant articles and documents
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.
